Mitochondrial DNA in inflammation and immunity

Joel S Riley1,2,* & Stephen WG Tait1,2,**

Abstract

Mitochondria are cellular organelles that orchestrate a vast range of biological processes, from energy production and metabolism to cell death and inflammation. Despite this seemingly symbiotic relationship, mitochondria harbour within them a potent agonist of innate immunity: their own genome. Release of mitochondrial DNA into the cytoplasm and out into the extracellular milieu activates a plethora of different pattern recognition receptors and innate immune responses, including cGAS-STING, TLR9 and inflammasome formation leading to, among others, robust type I interferon responses. In this Review, we discuss how mtDNA can be released from the mitochondria, the various inflammatory pathways triggered by mtDNA release and its myriad biological consequences for health and disease.

Keywords cell death; inflammation; immunity; mitochondria; mtDNA

Introduction

Serving as a first line of defence, the innate immune system guards us against a plethora of insults and invading microorganisms. Infection by pathogenic agents is detected in cells by pattern recognition receptors (PRRs) which recognise specific pathogen-associated molecular patterns (PAMPs). PRRs can be broadly classified into four distinct groups: NOD-like receptors (NLRs), Toll-like receptors (TLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) and C-type lectin receptors (CLRs) [1]. Upon detection of a PAMP, PRRs initiate a multitude of different signalling pathways, which culminate in the up-regulation of various type I interferons, pro-inflammatory chemokines and cytokines. These prime the adaptive immune system and create a hostile environment for the microorganism in which to survive. Additionally, damage-associated molecular patterns (DAMPs) are immune triggers that arise from the cell itself, such as proteins or DNA, and can activate innate immune pathways [2].

Mitochondria first appeared in eukaryotic cells about two billion years ago as α-proteobacterium, in what is thought to be an endosymbiotic relationship [3,4]. Over time, these bacteria evolved to become the much-studied organelle that we know today, playing crucial roles in metabolism, calcium homeostasis and cell death. Nevertheless, they have maintained an independent genome, which encodes 37 genes, comprised of 13 mRNAs forming key components of the oxidative phosphorylation system, in addition to 2 ribosomal RNA components and 22 tRNAs [3,4]. An estimated 1,000 proteins are located in the mitochondria, all of which, except those encoded by mtDNA, are translated in the cytosol and imported into the mitochondria [5].

Mitochondrial DNA itself is a circular molecule of double-stranded (ds)DNA. Transcription of both the heavy and light strand results in long, full-length transcripts which are processed by RNase enzymes to produce mature mRNA, tRNA and ribosomal RNA. In mammals, the polymerase responsible for mtDNA replication is DNA polymerase γ, but as POLγ cannot replicate dsDNA, the DNA helicase Twinkle is required to act directly before to unwind the DNA structure. Newly synthesised single-stranded (ss)DNA is bound by mitochondrial single-stranded DNA-binding protein to prevent secondary structure formation and attack by nucleases. Mitochondrial DNA replication has recently been reviewed extensively elsewhere [6]; here, we focus on the unique aspects of mtDNA which make it immunostimulatory. We will then discuss how mtDNA which is ejected from the mitochondria under specific circumstances can activate different innate immune pathways, including cGAS-STING signalling, inflammasomes and Toll-like receptors. We will also focus on the role of mtDNA in the formation of neutrophil extracellular traps (NETs) and the transfer of mtDNA between cells.

Mitochondrial DNA as a stimulator of the immune system

Potentially stemming from its bacterial origin, mitochondrial DNA is sensed as “foreign”, suggesting that it is seen differently to “self” DNA in cells. One example of this can be seen in its methylation status, where many studies have reported mtDNA to be hypomethylated compared to nuclear DNA [7,8], despite the presence of DNA methyltransferases in the mitochondria [9,10]. Some groups have reported aberrant methylation patterns of mtDNA, including 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) at CpG motifs [9–14], although others have proposed technical limitations to this work and using more sensitive techniques report that mtDNA
oxidation, resulting in mtDNA mutations which can contribute to reactive oxygen species. Due to this, it is particularly vulnerable to proximity to the electron transport chain, a major source of reactive oxygen species. As we shall discuss further in this Review, and in fact, a number of studies showing an absence of CpG methylation are correct, then mtDNA would harbour unmethylated CpG motifs similar to bacterial DNA, which could potentially activate pattern recognition receptors such as TLR9, absent in melanoma 2 (AIM2) and cGAS [15–18]. Mitochondrial DNA replication and transcription itself may represent a rich source of potential activators of DNA pattern recognition as we shall discuss further in this Review, and in fact, a number of studies showing an absence of CpG methylation are correct, then mtDNA would harbour unmethylated CpG motifs similar to bacterial DNA, which could potentially activate pattern recognition receptors such as TLR9, absent in melanoma 2 (AIM2) and cGAS [15–18]. Mitochondrial DNA replication and transcription itself may represent a rich source of potential activators of DNA pattern recognition receptors; for example, RNA:DNA hybrids form during transcription, in addition to long stretches of ssDNA and R-loops composed of RNA:DNA hybrids with a non-template ssDNA which can be recognised by cGAS [16].

Mitochondrial DNA exists in the mitochondrial matrix in close proximity to the electron transport chain, a major source of reactive oxygen species. Due to this, it is particularly vulnerable to oxidation, resulting in mtDNA mutations which can contribute to the pathogenesis of cancer [17], diabetes [18] and ageing [19]. It was thought the cell had limited capacity to repair mtDNA; however, multiple repair pathways are now well characterised [20]. Mitochondrial DNA is often schematically represented as a plasmid structure; however, this is an over-simplification. Rather, super-resolution imaging has revealed that it is densely compacted into nucleoids consisting of one copy of mtDNA and a number of different proteins [21], the most notable of which is mitochondrial transcription factor A (mtTFA, commonly referred to as TFAM). It might be assumed that the compaction of mtDNA into protein structures shields DNA from recognition, but this is not the case as we shall discuss further in this Review, and in fact, a number of studies have shown that TFAM itself might be immunostimulatory [13,14].

In a landmark study in 2004, Collins et al [22] found that injecting mtDNA into the joints of mice resulted in localised inflammation...
and arthritis. Further investigation revealed that the inflammation was dependent on the presence of oxidatively damaged bases in the mtDNA, as injection of an oligodeoxynucleotide (ODN) with the same sequence but without the oxidised residue had no effect. The observation that mtDNA can elicit potent immune responses opened a whole new field of research, and it is now appreciated that mtDNA can stimulate many PRRs, including cGAS, TLR9 and inflammasomes (Fig 1). Release of mtDNA from mitochondria and subsequent recognition by PRRs occurs during many cellular processes, including infection, cell death and neurodegeneration, and this will be the focus of the rest of this Review.

mtDNA-dependent activation of cGAS–STING signalling

mtDNA release in infection

Through necessity, cells have evolved elegant systems to detect the presence of invading pathogenic DNA. Cyclic GMP-AMP synthase (cGAS) is one such direct detector, which binds dsDNA to form a dimer [23,24]. C GAS then undergoes a conformational change which facilitates the conversion of ATP and GTP into 2′,3′-cyclic GMP-AMP (cGAMP) [25–31]. cGAMP is a second messenger, which binds the endoplasmic reticulum (ER)-resident protein stimulator of interferon genes (STING) inducing a conformational change in its C-terminal tail. TANK-binding kinase 1 (TBK1) is recruited to STING which phosphorylates it and the transcription factor interferon regulatory factor 3 (IRF3), eliciting the transcription of hundreds of interferon stimulatory genes (ISGs) that are potently anti-viral [32] (Fig 2). cGAS was assumed to be primarily cytosolic to avoid persistent activation by self-DNA in the nucleus, but recent work has shown it to be present in the nucleus [33,34] and at the plasma membrane [35]. A recent attempt to resolve these discrepancies by Volkman et al [36] reveals a more complex model than the cytosolic DNA sensing paradigm. The authors show that the majority of cGAS protein is nuclear, and they propose a model where cGAS must be “desequestered” prior to its full activation. However, it remains unclear how cytosolic DNA can be detected by cGAS, if cGAS is tethered in the nuclear compartment. Three independent studies were the first to show that mtDNA released from mitochondria is able to activate cGAS–STING signalling [37–39]. White et al and Rongvaux et al explored mtDNA release in the context of cell death (discussed later in this Review), whereas West et al provided evidence that TFAM deficiency promotes mitochondrial stress and mis-packaged mtDNA, resulting in their ejection into the cytoplasm where they bind and activate cGAS initiating a type I interferon response [39] (Fig 2). Of pathophysiological relevance, infection with Herpes simplex virus-1 (HSV-1) or vesicular stomatitis virus (VSV) results in mtDNA stress, TFAM depletion and mtDNA entrance into the cytoplasm. The cytoplasmic mtDNA is then sensed by cGAS, triggering cGAS–STING signalling leading to the up-regulation of a plethora of interferon genes, conferring an anti-viral state on the cell. Importantly, 

© 2020 The Authors

EMBO reports 21: e49799 | 2020

Figure 1. Overview of pro-inflammatory signalling pathways engaged by mitochondrial DNA. Mitochondrial DNA (mtDNA) can trigger various pro-inflammatory signalling pathways by endosomal localised TLR9 or via cytosolic cGAS–STING or via cytosolic inflammasome (AIM2 or NLRP3). Top: TLR9 binds mtDNA in the endosome eliciting an NF-κB-dependent pro-inflammatory signalling program. Middle: cGAS recognises mtDNA in the cytosol and activates endoplasmic reticulum (ER)-localised STING triggering an interferon response. Bottom: mtDNA-dependent inflammasome activity leads to caspase-1-dependent maturation or pro-inflammatory IL-1 and IL-8.
degrades mtDNA, resulting in complete loss of mtDNA in infected cells [40,41]. Removal of mtDNA in infected cells does not appear to impact HSV replication [42]. Furthermore, exonuclease activity is required for effective viral DNA production to maintain cell-to-cell infectivity, though whether this is related to UL12.5’s mtDNA-targeted nuclease activity is unknown [43].

Curiously, infection with RNA viruses, such as dengue virus, also elicits a cGAS-STING response, despite cGAS being a DNA-specific PRR [44]. Several studies have now shown that dengue virus causes the release of predominantly oxidised mtDNA into the cytosol, where it can activate both cGAS [45,46] and TLR9 [47]. Dengue virus has evolved strategies to circumvent cytosolic mtDNA-induced cGAS signalling during infection by encoding proteases which target cGAS and STING for degradation, thus ensuring persistence of the virus [46,48,49].

Infection with the bacterial pathogen Mycobacterium tuberculosis triggers cGAS activation and subsequent IRF3-dependent type I interferon response [50–52]. This was assumed to be solely due to detection of mycobacterium DNA, but other studies have identified a role for mitochondrial stress and ensuing release of mtDNA into the cytosol [53]. This observation is strain-dependent but does propose a role for mitochondrial stress and dynamics on the M. tuberculosis-induced release of mtDNA. Previous work has observed cytochrome c release from mitochondria in cells infected with M. tuberculosis, indicating that there may be a possible role for BAX/BAK-dependent mitochondrial permeabilisation (discussed in detail later) in infection-related mtDNA release [54] (Fig 2).

Pathogen-infected cells often secrete IL-1β due to inflammasome activation. A recent report by Aarreberg et al discovers a link between IL-1β secretion in infected cells, which can then activate a cGAS-STING-dependent type I interferon response in surrounding bystander cells. Interestingly, IL-1β stimulation of bystander cells increases mitochondrial mass, decreases mitochondrial membrane potential and induces mtDNA release [55]. However, mtDNA release is observed in the absence of detectable cytochrome c release and cell death, suggesting that this is not the mechanism of mtDNA release, although it does not rule out limited mitochondrial permeabilisation seen by us and others in the context of infection (see below). This is not the first time IL-1R signalling has been implicated in cell-intrinsic defence [56–58], but it is the first to suggest that mtDNA release plays a key role in the initiation of cGAS-STING signalling in the bystander cells.

### mtDNA activation of cGAS-STING during cell death

During programmed cell death, the pro-apoptotic proteins BAX and BAK permeabilise the mitochondrial outer membrane to allow the passage of pro-apoptotic molecules to move from the inner membrane space into the cytosol, where they can initiate a caspase cascade, resulting in a rapid cell death [59]. White et al and Rongvaux et al showed that in the absence of apoptotic caspase activation, mtDNA activates cGAS in a promiscuous manner, which in vivo leads to mildly elevated IFN-β protein levels in blood, though a level sufficient to induce the expression of interferon-stimulated genes [37,38] (Fig 3). This suggests that apoptotic caspases play a crucial role in dampening type I interferon responses in dying cells, maintaining the “immune-silent” nature of apoptosis (Fig 3). Further work has shown that apoptotic caspases directly cleave cGAS, IRF3 and mitochondrial anti-viral signalling protein (MAVS),...
key proteins required for the production of type I interferon [60], supporting the notion that caspases dampen the immune response during cell death. High-resolution imaging studies have further expanded our understanding of how mtDNA is released from the mitochondria during cell death. We and others recently showed that BAX and BAK can permeabilise the mitochondrial outer membrane, but in the context of caspase inhibition these pores grow dramatically, sufficient to allow inner membrane herniation and extrusion of mtDNA [61–63] (Fig 3). We found that under caspase-inhibited conditions, mitochondrial permeabilisation leads to down-regulation of inhibitor of apoptosis proteins (IAPs), NF-κB-inducing kinase (NIK) activation and an NF-κB transcriptional program, in addition to mtDNA release-induced cGAS-STING activation [64]. The cytokines and chemokines up-regulated via NF-κB after mitochondrial permeabilisation can serve to promote macrophage activation [64,65]. This leads to robust anti-tumour effects, highlighting a potential therapeutic role for caspase inhibition in cancer treatment [64]. Collectively, these results help to reconcile how predominantly cytosolic cGAS can be activated by mtDNA during cell death. Nevertheless, a number of unresolved questions remain. Firstly, is inner membrane permeabilisation a regulated process, and if so, how? A rapid inner membrane permeabilisation of sufficient size to allow the passage of small ions is observed minutes after outer membrane permeabilisation [61], but is insufficient to allow mtDNA nucleoid extrusion and is probably only transient, as inner membrane potential can be maintained after outer membrane permeabilisation [66–69]. Secondly, there are cell type differences in the degree of inner membrane permeabilisation, as different studies report varying degrees of mtDNA release during cell death [61,62], implying that specific cell-intrinsic factors play a role in inner membrane permeabilisation. Finally, the physiological relevance of cell death-related mtDNA release is unknown. Most cell types undergo rapid and complete caspase-dependent apoptosis in vivo, presumably limiting any potential for mtDNA-driven inflammation during cell death. However, some cell types, for instance cardiomyocytes, display deficient caspase activity downstream of mitochondrial permeabilisation [70]. Such cells might generate a greater type I anti-viral interferon response after mitochondrial permeabilisation. Alternatively, cGAMP might transfer from apoptotic to healthy cells, serving as an “early warning” defence system, instructing healthy cells to transcribe genes important for their survival (Fig 4) [71,72].

In addition to DNA, mitochondria also possess dsRNA which is known to be potentially immunogenic [73]. Mitochondrial dsRNA arises from transcription of both the heavy and lights strands of mtDNA; however, although the light strand is rapidly degraded the heavy strand is not, and nearly all the dsRNA detected in the cytoplasm are of mitochondrial origin. The mitochondrial helicase SUV3 and polynucleotide phosphorylase PNPase dampen the accumulation of dsRNA, but when these are depleted, dsRNA accumulates in the cytoplasm where it activates a type I interferon response driven by the dsRNA receptor MDA5 [74]. Silencing of BAX and BAK suppresses the type I interferon response, strongly suggesting that BAX/BAK-dependent mitochondrial outer membrane permeabilisation is responsible for mitochondrial dsRNA escape into the cytoplasm [74]. Furthermore, patients with mutations leading to a decrease in PNPT1, the gene that encodes PNPase protein, exhibit greater accumulation of dsRNA and elevated interferon levels in their serum [74].

Mitochondrial outer membrane permeabilisation is a rapid and complete event, spreading to all mitochondria in a cell. Following formation of BAX/BAK pores, pro-apoptotic proteins such as cytochrome c are released from the intermembrane space where they initiate the caspase cascade, culminating in cell death. However, we have found that under conditions of sub-lethal stress, a limited number of mitochondria in a cell can undergo permeabilisation, called minority MOMP, leading to genomic instability and

---

**Figure 3. BAX/BAK-dependent initiation of inflammation.**

Following a pro-apoptotic stress, BAX and BAK are activated leading to mitochondrial outer membrane permeabilisation. This enables the release of caspase-activating proteins from the mitochondrial intermembrane space. Following this, macropores form on the mitochondrial outer membrane causing extrusion and permeabilisation of the inner membrane. This enables release of mtDNA. Mitochondrial double-stranded RNA (dsRNA) can also be released. Collective release of these molecules triggers inflammation via MAVS, cGAS-STING and NF-κB. Caspase activity is anti-inflammatory, in part, through direct cleavage and inactivation of inflammatory signalling molecules.
transformation [75]. A recent report by Brokatsky et al reveals a link between pathogen invasion and activation of mitochondrial cell death machinery [76]. In this study, it was found that various pathogens can induce limited mitochondrial permeabilisation. It remains unclear how pathogens can trigger minority MOMP, but nevertheless they can, resulting in mtDNA release (presumably through BAX/BAK pores), stimulating cGAS-STING activation and cytokine secretion [76].

How else might mtDNA be released from mitochondria? Another potential mechanism for mtDNA release from mitochondria is through the mitochondrial permeability transition pore (mPTP) [77,78]. The exact composition of the pore is unclear, although there seems to be consensus that cyclophilin D is present [79]. The mPTP spans the mitochondrial inner membrane and forms in response to high mitochondrial calcium concentration and various other cellular stresses. However, the mPTP is predicted to only allow the efflux of molecules smaller than 1.5 kDa, much smaller than a mtDNA nucleoid [80,81]. In line with this, studies have shown that only fragments of mtDNA can pass through the mPTP [77,82,83]. It remains possible that sustained opening of the pore can lead to swelling of the mitochondria and subsequent rupture of the inner membrane, which would permit the efflux of mtDNA into the cytoplasm. The involvement of mPTP in mtDNA release during cell death has been ruled out [61], but chitosan, a vaccine adjuvant, appears to induce a cGAS-STING- and mPTP-dependent type I interferon response. This is possibly due to mtDNA release, though a direct role for mtDNA has not been rigorously assessed [84]. An intriguing recent report suggests that cells experiencing mitochondrial stress caused by the lack of mitochondrial endonuclease G release mtDNA through pores formed by oligomers of the voltage-dependent anion channel (VDAC) [85]. As mitochondrial DNA release is thought to play a role in the pathogenesis of lupus

Figure 4. Non-cell autonomous effects of mtDNA.
(A) Upon pathogen encounter, neutrophils can extrude DNA (both nuclear and mitochondrial) that forms an extracellular trap for extracellular microbes. Due to pro-inflammatory properties, these DNA neutrophil extracellular traps (NETs) can also have pathological effects in diseases such as lupus. (B) mtDNA can transfer via exosomes or in intact mitochondria to neighbouring cells, impacting on the metabolism and survival of the recipient cell. Inflammatory responses to mtDNA can also have non-cell autonomous effects. The cGAS-induced secondary messenger cGAMP has been shown to transfer via gap junctions eliciting anti-viral interferon responses in neighbouring cells.
[86,87], a role for VDAC pore formation was tested in an in vivo model of lupus-like disease. Using the VDAC1 oligomerisation inhibitor VBIT-4, the authors were able to reduce lupus-like symptoms in lupus-prone mice, providing a rationale to target VDAC-mediated mtDNA release in this disease [85].

**Therapeutic targeting of mtDNA-dependent cGAS-STING activity**

There is currently intense interest in the development of inhibitors and activators of the cGAS-STING pathway, depending on the disease. In humans, the systemic inflammatory disease Aicardi-Goutières syndrome (AGS) is characterised by mutations in a number of different genes involved in DNA sensing [88]. For example, TREC1, a DNA exonuclease, is frequently mutated in human patients with AGS and systemic lupus erythematosus (SLE) [89–91], and co-deletion of cGAS, STING, Interferon-α/β receptor (IFNAR) or IRF3 rescues this phenotype [92–98]. Accumulation of cytosolic DNA appears to be a defining characteristic of AGS and SLE, as deletions in DNA- and RNA-related genes including SAMDH1, a DNA exonuclease and RnaseH2 are frequent [99–102]. Gain-of-function mutations in STING itself lead to an up-regulation of type I interferon responses and lupus-like symptoms in patients [103,104]. DNase II deficiency in humans leads to autoinflammation with increased type I IFN [105] and in mice causes arthritis [106]. This is thought to be due to the lack of self-DNA degradation in dead cells engulfed by macrophages resulting in sustained cGAS-STING stimulation [98,106,107], and AIM2 inflammasome formation [108,109] with a possible contribution of endosomal TLRs [108]. Myocardial infarction (MI) is another condition known to involve a strong inflammatory component. King et al [110] showed that ischaemic cell death and engulfment by macrophages drives an IRF3-dependent type I IFN response. Genetic or pharmacological disruption of cGAS-STING signalling in mice improved their outcomes post-MI, proposing this signalling axis as suitable for therapeutic intervention in patients [110,111]. While it is not clear if this is due to mtDNA release per se, increased mtDNA in plasma from patients with heart disease has been frequently observed [112–114]. Clearly, inhibiting the cGAS-STING pathway in these disease settings might be beneficial to patients. Small molecules targeting both cGAS [115,116] and STING [117] have been developed, with STING antagonists emerging as the most promising. Blocking the IFNAR receptor to block interferon signalling in SLE patients had seemed like a viable therapeutic route; however, late-stage clinical trials in this area have failed, prompting more investigation of how important interferon signalling is in the pathogenesis of SLE.

The ability to turn immunologically “cold” tumours “hot” and make them more responsive to immunotherapy is a desirable outcome in cancer treatment. Efficient T-cell responses to tumour cells is a critical step to durable cancer treatment control [118]. STING is required for spontaneous CD8+ T-cell priming in vivo [119]. Mechanistically, dying tumour cells transfer their DNA to antigen-presenting dendritic cells when phagocytosed, eliciting cGAS-STING-IRF3 signalling leading to an anti-tumour T-cell response [119–121]. Activation of STING by addition of exogenous cGAMP can also enhance anti-tumour immunity after irradiation [120], the first evidence that therapeutic activation of STING may improve cancer therapy. This effect was later shown to be exclusive to dendritic cells over macrophages; blockade of the “don’t eat-me” signal CD47 results in increased tumour-originated mtDNA in the cytosol of DCs and is required for the cross-priming and type I IFN response mediated through cGAS [122]. Dying tumour cells transfected with exogenous cytosolic DNA, viral DNA or cyclic dinucleotides (CDNs) have a greater capacity to activate STING signalling in antigen-presenting cells, enhancing T-cell priming and expansion of anti-tumour T cells [123]. Therefore, it is also possible that mtDNA may act as a STING activator in antigen-presenting cells (APCs) under certain circumstances, for example when apoptotic caspases are inhibited. Another example of immune cell communication is in the interaction of T cells with antigen-presenting dendritic cells. Upon formation of an immunological synapse between these two cell types, T cells shed extracellular vesicles (EVs) containing genomic and mtDNA. These EVs are taken up by the dendritic cell, triggering a cGAS-STING-dependent anti-viral response, conferring resistance to subsequent viral infection [124]. In the context of cancer treatment, it is plausible that apoptotic cell-containing dendritic cells could stimulate a similar effect in T cells, generating longer lived dendritic cells for more durable treatment responses [125]. Together, these data and many others provide a rationale for enhancing STING signalling in cancer treatment, and this is currently under active investigation [126,127].

**mtDNA release, cGAS-STING and neurodegeneration**

Under normal, homeostatic conditions, damaged or stressed mitochondria are eliminated from the cell by a type of mitochondrial-selective autophagy called mitophagy [128]. Mutations in proteins involved in mitophagy pathways can contribute to neurodegeneration. This is perhaps best evidenced for PINK1/Parkin-dependent mitophagy. For instance, loss-of-function mutations in the PINK1/Parkin pathway of mitophagy associate with early onset Parkinson’s disease [129–133]. In a simplified view, the kinase PINK1 is activated on dysfunctional mitochondria where it phosphorylates ubiquitin. Phospho-ubiquitin allosterically activates the E3 ubiquitin ligase Parkin leading to enhanced mitochondrial ubiquitination that serves as an autophagic signal to remove the damaged mitochondrion [134–136]. Parkinson’s disease is associated with neuroinflammation [137], and the serum from Parkinson’s patients is often enriched for pro-inflammatory cytokines, including TNF, IL-1β, IFNγ and IL-6 [138,139]. However, many of the studies elucidating the mechanistic basis of Parkinson’s have been performed in cultured cell lines, and despite much effort, the in vivo relevance of PINK1/Parkin-mediated mitophagy was not well understood, particularly since mice that lack either PINK1 or Parkin exhibit no Parkinson’s-like disease phenotypes [140–142]. Knowing that defective mitophoria can release innate immune-activating DAMPs, Sliter et al [143] investigated the effect of exhaustive exercise or mtDNA mutation on inflammation. When challenged with exhaustive exercise, Parkin−/− or PINK1−/− mice displayed higher serum levels of pro-inflammatory IL-6 and IFN-γ when compared to wild-type mice, in addition to increased levels of uncleared mitochondria. Remarkably, this could be completely rescued by deletion of STING or administering IFNα-blocking antibody to mice, strongly suggesting that mtDNA released from damaged mitochondria that are not cleared is responsible for the inflammation observed in Parkinson’s patients. Interestingly, the authors also observed increased circulating mtDNA in Parkin−/− mice following exhaustive exercise, meaning that the mtDNA is not only extruded from mitochondria but also exits the cell. Mutator mice expressing a proofreading-defective mtDNA
polymerase (PolG) accumulate mutations in mtDNA, which instead of causing neurodegeneration results in dopaminergic neuron loss and defective movement. While no difference in inflammatory cytokine levels was noted between wild-type, Parkin<sup>−/−</sup> or mutator mice, Parkin<sup>−/−</sup>:mutator mice do have higher serum cytokine levels. Again, cytokine levels and the movement disorder could be completely rescued by co-deletion of STING, reinforcing the cGAS-STING axis as the major player in Parkinson’s-associated inflammation. However, further work is needed to elucidate the absolute requirement for mtDNA over nuclear DNA and the precise mechanism of how mtDNA is released from the mitochondria.

**mtDNA as an inflammasome activator**

Inflammasomes are multi-subunit complexes which form in response to exogenous PAMPs and DAMPs [144]. One of four receptors—absent in melanoma 2 (AIM2), NOD, LRR and Pyrin domain-containing protein 1 (NLRP1), NLRP3 or NLR family CARD domain-containing protein 4 (NLRC4), bind to the adaptor molecule ASC forming a platform for the dimerisation, autophosphorylation and activation of caspase-1. Active caspase-1 can then process pro-IL-1β and pro-IL-18 into their mature form so they can be secreted (see Fig 1). The first report of mtDNA acting as an activator of inflammasomes came in 2011 when Nakahira et al [145] reported that depletion of proteins involved in autophagy leads to an accumulation of dysfunctional, persistent mitochondria exhibiting excessive ROS. These mitochondria were more prone to extrude mtDNA into the cytoplasm upon stimulation with lipopolysaccharide (LPS) or ATP, dependent on the ability to from NLRP3 inflammasomes. Interestingly, Nakahira et al suggested that as well as acting downstream of mtDNA release, NLRP3 also acts upstream, to facilitate mPTP formation on the mitochondria allowing mtDNA release. However, as already discussed, whether mPTP is sufficient to allow mtDNA translocation from the mitochondrial matrix into the cytoplasm is debatable. Extending this work, the following year Shimada et al [146] reported that during macrophage apoptosis mtDNA is released and binds NLRP3. Notably, NLRP3 appears to have a preference for oxidised mtDNA, clarifying the observations that ROS plays a crucial role in inflammasome activation [147]. Linking these observations, deletion of the autophagy receptor p62 prevents mitophagic clearance of mitochondria damaged by NLRP3 agonists, exacerbating inflammasome formation and IL-1β secretion [148]. More recent work has pointed to newly synthesised, oxidised mtDNA as the species which binds NLRP3 [149]. Zhong et al discovered that levels of the mitochondrial deoxyribonucleotide kinase CMPK2 increase upon LPS stimulation. CMPK2 catalyses a step in the synthesis of the nucleotide cytidine triphosphate, which is rate-limiting for mtDNA synthesis. Elevated dCTP levels in turn increase mtDNA replication, which is oxidised by ROS and released into the cytoplasm where it can activate NLRP3 and stimulate IL-1β secretion. However, the role of NLRP3 as a direct sensor of DNA is contentious, as many disparate signals have been reported as the common signal for NLRP3 activation [144]. Indeed, recent work from the Chen laboratory has shown that dispersal of the trans-Golgi network following K<sup>+</sup> efflux is the likely common trigger [150].

Supporting the notion that inflammasomes and caspase activity can act upstream of mtDNA release, there are reports that caspases cause mitochondrial damage. For example, inflammasome-activated caspase-1 has been reported to damage mitochondria and promote the release of cytochrome c, indicative of mitochondrial outer membrane permeabilisation [151]. The authors suggest that this is due to mPTP formation, although a role for BAX and BAK was not rigorously assessed in this work. Impairment of mitophagy was also implicated, as Parkin was found to be a substrate of caspase-1 in macrophages, leading to an accumulation of damaged, ROS-producing macrophages [151]. Furthermore, during infection-related ER stress, NLRP3 (but not the adaptor protein ASC or caspase-1) is involved in caspase-2 activation and cleavage of the pro-apoptotic protein BID, promoting mitochondrial permeabilisation [152].

**Neutrophil extracellular traps**

So far, we have mainly discussed the cell autonomous role of mtDNA release; however, it is becoming clear that mtDNA can also be extruded from the mitochondria, into the cytoplasm and outward further into the extracellular space. One interesting example of this is in the generation of neutrophil extracellular traps, and in particular the role of mtDNA in their formation (Fig 4).

Neutrophils are the first line of attack in infection, capable of engulfing pathogens and degranulating, the process of releasing soluble anti-microbials. In 2004, Brinkmann and colleagues discovered that upon stimulation with IL-8, phospholipase A2 (PLA2) or LPS, neutrophils extruded vast fibrous networks, which they termed neutrophil extracellular traps (NETs) [153]. Analysis of these NETs showed that they contained a variety of microbial-killing proteins, including elastase, cathepsin G and myeloperoxidase. However, they also contain DNA, as noted by reactivity with antibodies against histones and DNA intercalating dyes. Successive work showed that NETs were also enriched for mtDNA [154–156]. NET formation has been well studied in patients with systemic lupus erythematosus (SLE), an autoimmune condition hallmarked by the appearance of autoantibodies against dsDNA and RNA-protein complexes, resulting in elevated type I interferon responses. A number of studies show that mtDNA is part of NETs formed in SLE. Caielli et al [87] found that in healthy neutrophils, mitochondria with oxidative damage are removed not via mitophagy, but by extruding their mitochondrial matrix contents, including TFAM-mtDNA nucleoids, into the extracellular space. These TFAM-mtDNA nucleoids are devoid of oxidised DNA, and so do not activate plasmacytoid dendritic cells (pDCs) and thus are not immunogenic. Healthy neutrophils remove oxidised mtDNA by signalling PKA phosphorylation of TFAM which initiates its degradation and by shutting oxidised mtDNA into lysosomes. In contrast, neutrophils in SLE have reduced PKA activation and so do not degrade TFAM as efficiently, leading to the extrusion of immunogenic oxidised mtDNA [87]. Another report reveals ROS to be an important mediator for neutrophils to produce oxidised mtDNA-containing NETs in response to stimulation by ribonucleotide immune complexes (RNP ICs) [86]. The authors also found that injecting this DNA was pro-inflammatory and dependent on the STING pathway revealing a dual role for mitochondria in providing the source of DNA for NETs and oxidising it for maximal interferogenic response in SLE [86] (Fig 4). Sustained IFNα signalling in SLE is also known to deregulate mitochondrial
metabolism in monocytes, leading to reduced autophagy and an accumulation of mtDNA in the cytoplasm. This leads to cGAS-STING activation which promotes secretion of TNF and IL-6 and the expansion of self-DNA autoreactive lymphocytes [157]. It is now also appreciated that other cell types, including lymphocytes and eosinophils, can secrete mtDNA-containing webs which act to prime type I interferon responses in peripheral blood mononuclear cells [158,159].

Nuclear DNA is prepared for expulsion as NETs through a highly regulated process involving decondensation of chromatin and ctitulination of histones. Furthermore, plasma membrane permeabilisation is also regulated, inevitably leading to cell death. Within minutes of stimulation, neutrophils rapidly produce NETs, whereas the death of neutrophils (dubbed “NETosis”) occurs ~2 h after [160]. While these two phenomena are often conflated in the literature, the timing argues against a general lytic mechanism of mtDNA release. In fact, release of mtDNA as NETs seems to be energy-dependent [161]. The precise mechanism of mtDNA escape during NET formation remains to be elucidated; one possibility is that it may be due to BAX/BAK pore formation on the mitochondrial outer membrane [61,62], although this seems unlikely as this would induce a rapid cell death.

### mtDNA and TLR9

The Toll-like family of receptors (TLR) recognise a plethora of different bacterial features to instigate innate immunity. TLR9 recognises hypomethylated CpG motifs found in bacteria. TLR9 is expressed primarily in monocytes, macrophages, plasmacytoid dendritic cells and B lymphocytes. In resting cells, TLR9 resides on the endoplasmic reticulum, but recognition of DNA occurs in the endolysosomes (see Fig 1) [162–165]. DNA-bound TLR9 recruits MyD88 which activates MAPK and NF-κB, inducing an inflammatory response. In common with bacterial DNA, mtDNA is hypomethylated at CpG motifs, making it a potent activator of TLR9 [166,167]. mtDNA detection by TLR9 was first noted in 2010 by Zhang et al, who observed that during systemic inflammatory response syndrome (SIRS) mtDNA was released into the blood where it can activate TLR9 on neutrophils [168,169]. In the heart, autophagy is required to remove damaged mitochondria and maintain heart function during hemodynamic stress [170]. However, when DNase II, a lysosomal DNase, is deleted from cardiac cells, the mice succumb faster following heart pressure overload [171]. Delving deeper into the mechanism, the authors found that this was due to an increase in mtDNA which has escaped degradation, thus activating a TLR9-dependent inflammatory response [171]. Mitochondrial DNA released from dying cells or as part of NETs can form a complex with the anti-microbial peptide LL-37. This mtDNA:LL-37 complex evades degradation by DNase II and can activate TLR9 on pDCs, neutrophils and endothelial cells to exacerbate atherosclerosis [172]. High-mobility group box 1 (HMGB1) is a DNA-binding protein released from necrotic [173] and cytokine-stimulated cells [174]. HMGB1 binds a receptor, called RAGE, leading to inflammatory signalling. In particular, HMGB1 has been shown to be released from pDCs following stimulation with CpG oligodeoxynucleotides (ODNs). CpG-ODNs can bind and activate TLR9, but when complexed with HMGB1 the inflammatory response is augmented through HMGB1 activation of RAGE [175]. In an analogous manner, TFAM co-operates with mtDNA released from necrotic cells to increase pro-inflammatory signalling in pDCs through RAGE and TLR9 [176,177].

TLR9 has been particularly well studied in liver pathologies. In liver cancer, hypoxia triggers the translocation of mtDNA and HMGB1 into the cytoplasm of cancer cells to activate TLR9, resulting in tumour cell proliferation [178]. TLR9 is crucial for the development of acetaminophen-induced hepatotoxicity [179] and fibrosis [180]. Development of non-alcoholic steatohepatitis (NASH) involves innate immunity, with hepatic stellate cells and macrophage-like Kupffer cells being particularly relevant. Mice fed a choline-deficient amino acid-defined diet develop NASH, whereas TLR9−/− mice do not, implicating TLR9 as a requirement for NASH development [181]. The precise ligand for TLR9-derived liver disease was poorly understood, although the observation that NASH patients had higher mitochondrial mass, but reduced respiration, suggested that mitochondria may play a role [182]. In line with these observations, Garcia-Martinez et al [183] found that mice and human patients with NASH exhibited higher levels of oxidised mtDNA in hepatocytes and plasma. As the oxidation of mtDNA increases its ability to activate TLR9, the authors confirmed that was the case. Importantly, mice dosed with a TLR9 antagonist displayed reduced symptoms of NASH, validating the importance of mtDNA release and TLR9 signalling in the pathogenesis of NASH [183]. NASH is characterised by different forms of cell death, most prominently apoptosis [184] and necrosis [185,186]. In hepatocytes, mitochondrial permeabilisation results in an increase of DNase II activity, and knockdown of DNase II switches the mode of cell death to a RIP1-dependent non-apoptotic form [187]. Importantly, this is due to the release of mtDNA after mitochondrial permeabilisation, which triggers TLR9 signalling and subsequent IFNβ secretion. In mice fed a high-fat diet, a model of NASH, DNase II activity is diminished, providing a mechanistic link as to how necrosis of hepatocytes can augment NASH symptoms in patients [187]. It is unclear why the release of mtDNA triggers either cGAS-STING or TLR9 signalling in different studies; however, it may be due to different cell types, length or oxidation status of mtDNA, activity of DNA nucleases or different cellular compartments.

Mutations in OPA1, a protein required for mitochondrial inner membrane fusion and cristae formation, have been reported to cause mtDNA instability [188–191]. Deletion of OPA1 in skeletal muscle, a tissue with high metabolic demands, predictably results in mitochondrial dysfunction, mtDNA stress and inflammation leading to reduced growth and early death in mice [192,193]. Interestingly however, OPA1 deletion leads to disruption of mitophagy due to impaired autophagic flux resulting in higher levels of dysfunctional mitochondria in these tissues [194]. When mtDNA localisation was examined, following OPA1 deletion there is high co-localisation of mtDNA and TLR9, implicating TLR9 as the driver of OPA1-deletion inflammation [194].

### Transfer of mtDNA between cells

So far, this Review has mainly focussed on the cell-intrinsic biological effects of mtDNA release. However, it is possible that released
Mitochondria are multi-faceted organelles orchestrating key events in both life and death. They represent a rich source of DAMPs which can potently trigger the innate immune system, such as ATP, formyl peptides and mtDNA. Possibly stemming from its bacterial origin, mtDNA is particularly effective at initiating inflammatory and anti-viral signalling.

The last number of years has seen an explosion in interest in how mitochondria initiate innate immunity in the context of pathogen invasion, cell death and pathology. However, many of these studies leave us with unresolved questions as to precisely how mtDNA is extruded from the mitochondria. In the context of cell death, it is now clear that BAX and BAK form the pores on the mitochondrial outer membrane through which the inner membrane herniates, leading to mtDNA release, although how the inner membrane permeabilises is as yet not fully resolved [61,62]. Many other studies have suggested that the mPTP is involved in various contexts, but again this is controversial. Clearly, further investigation is required, whether to determine a more universal role for BAX/BAK-dependent mtDNA release, utilising our current knowledge of the nature of the mPTP, or whether an altogether unknown mechanism is involved.

It is also apparent that cellular context will determine how mtDNA causes inflammation. cGAS-STING signalling seems to be widely available across most cell types, a notable exception being some transformed cells. However, TLR9 protein expression appears to be restricted to immune cells, as does expression of inflammasome components. Perhaps most interesting will be determining what the outcomes of triggering innate immunity with cytosolic or cell-free mtDNA are. For example, in the context of cell death, does production of cGAMP in apoptotic cells transfer to healthy apoptotic cells via gap junctions to promote a death-resistant state, in a manner similar to what has been observed in astrocytes [71]? Pathogen invasion stimulates a limited degree of mtDNA release by hijacking the apoptotic machinery, so it is plausible to see how this might act as a cell-intrinsic warning system, but it will be fascinating to understand how this functions in the context of a whole tissue. Furthermore, can we leverage what we have learnt about anti-viral signalling during cell death to enhance anti-cancer therapy by inhibiting caspases? Likewise, will our understanding of how mtDNA and STING function in neurodegeneration lead to novel therapeutic strategies to enhance healthy ageing [143]? Along these lines, mitochondrial dysfunction has been shown to induce a specific form of senescence termed MiDAS (mitochondrial dysfunction-associated senescence) [206]—given the links between ageing, senescence and inflammation, it is tempting to hypothesise that mtDNA plays a role in the initiation of this phenotype.

A broad spectrum of pathologies, from cancer, to autoimmunity and ageing all have aberrant mtDNA release as a driver or contributor of disease. Future work aimed at understanding how mtDNA is involved will no doubt afford us new therapeutic avenues with which to treat patients.
In need of answers

(i) Why do different tissue and cell types respond to cytosolic mtDNA through different pathways?
(ii) Can mtDNA release be harnessed therapeutically for treatment of inflammatory diseases or cancer?
(iii) Where is cGAS located in the cell?
(iv) What are the physiological, non-lethal effects of mtDNA release into the cytoplasm?

Conflicts of interest

The authors declare that they have no conflict of interest.

References

1. Brubaker SW, Bonham KS, Zanoni I, Kagan JC (2015) Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 33: 257–290
2. Gong T, Liu L, Jiang W, Zhou R (2019) DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 19: 95–112
3. Roger AJ, Muñoz-Gómez SA, Kamikawa R (2012). Fox TD (2015). Mechta M, Ingerslev LR, Fabre O, Picard M, Barrès R (2013). Infantino V, Castegna A, Iacobazzi F, Spera I, Scala I, Andria G, Iacomina/C20. Shock LS, Thakkar PV, Peterson EJ, Moran RG, Taylor SM (2015).
4. Sun Z, Terragni J, Jolyon T, Borgaro JG, Liu Y, Yu L, Guan S, Wang H, Sun D, Cheng X et al (2013) High-resolution enzymatic mapping of genomic 5-hydroxymethylcytosine in mouse embryonic stem cells. Cell Rep 3: 567–576
5. Hong EE, Okitsu CY, Smith AD, Hsieh C-L (2013) Regionally specific and genome-wide analyses conclusively demonstrate the absence of CpG methylation in human mitochondrial DNA. Mol Cell Biol 33: 2683–2690
6. Mankan AK, Schmidt T, Chauhan D, Goldeck M, Honing K, Gaidt M, Kubarenko AV, Andreeva L, Hopfner K-P, Hornung V (2014) Cytosolic RNA:DNA hybrids activate the cGAS-STING axis. EMBO J 33: 2937–2946
7. Chatterjee A, Mambo E, Sidransky D (2006) Mitochondrial DNA mutations in human cancer. Oncogene 25: 4663–4674
8. Jiang W, Li R, Zhang Y, Wang P, Wu T, Lin J, Yu J, Gu M (2017) Mitochondrial DNA mutations associated with type 2 diabetes mellitus in Chinese Uygur population. Sci Rep 7: 16989
9. Larsson N-C (2010) Somatic mitochondrial DNA mutations in mammalian aging. Annu Rev Biochem 79: 683–706
10. Kazak L, Reyes A, Holt IJ (2012) Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 13: 659–671
11. Kukat C, Wurm CA, Spähr H, Falkenberg M, Larsson N-G, Jakobs S (2013) Super-resolution microscopy reveals that mammalian mitochondrial nucleoids have a uniform size and frequently contain a single copy of mtDNA. Proc Natl Acad Sci USA 108: 13534–13539
12. Collins LV, Hajizadeh S, Holme E, Jonsson I-M, Tarkowski A (2004) Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J Leukoc Biol 75: 995–1000
13. Sun L, Wu J, Du F, Chen X, Chen ZJ (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339: 786–791
14. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ (2013) Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339: 826–830
15. Zhang X, Wu J, Du F, Xu H, Sun L, Chen Z, Brautigam CA, Zhang X, Chen ZJ (2014) The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep 6: 421–430
16. Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, Hayakawa Y, Hammond MC, Vance RE (2013) The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 3: 1355–1361
17. Gao P, Asciano M, Wu Y, Barchet W, Gaffney BL, Zillingler T, Senganov AA, Liu Y, Jones RA, Hartmann G et al (2013) Cyclic [G(2’)S(2’)?pA(3’)?S’]p is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153: 1094–1107
18. Civin F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G, Hornung V, Hopfner K-P (2013) Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498: 332–337
19. Gao P, Asciano M, Zillingler T, Wang W, Dai P, Senganov AA, Gaffney BL, Shuman S, Jones RA, Deng L et al (2013) Structure-function analysis of STING activation by cG(2’?5’?pA(3’)?S’)?p and targeting by antiviral DMXAA. Cell 154: 748–762
20. Kranzusch PJ, Lee AS-Y, Berger JM, Doudna JA (2013) Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep 3: 1362–1368
21. Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ (2013) Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 51: 226–235
32. Zhang C, Shang G, Gui X, Zhang X, Bai X-C, Chen ZJ (2019) Structural basis of STING binding with and phosphorylation by TBK1. Nature 567: 394 – 398
33. Gentili M, Lahaye X, Nadalín F, Nader GPF, Lombardi EP, Herve S, De Silva NS, Rookhuizen DC, Zueva E, Goudot C et al (2019) The N-terminal domain of cGAS determines preferential association with centromeric DNA and innate immune activation in the nucleus. Cell Rep 26: 2377 – 2393.e13
34. Liu H, Zhang H, Wu X, Ma D, Wu J, Wang L, Jiang Y, Fei Y, Zhu C, Tan R et al (2018) Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. Nature 563: 131 – 136
35. Barnett KC, Coronas-Serna JM, Zhou W, Ernandes MJ, Cao A, Kranzusch PJ, Kagan JC (2019) Phosphoinositide interactions position cGAS at the plasma membrane to ensure efficient distinction between self- and viral DNA. Cell 176: 1432 – 1446.e11
36. Volkman HE, Cambier S, Gray EE, Stetson DB (2019) Tight nuclear tethering of cGAS is essential for preventing autoactivity. Elife 8: 394 – 21
37. White MJ, McArthur K, Metcalf D, Lane RM, Cambier JC, Herold MJ, van Deelt MF, Bedouin S, Lossene G, Ritchie ME et al (2014) Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 159: 1549 – 1562
38. Rongvaux A, Jackson R, Harman CCD, Li T, West AP, de Zoete MR, Wu Y, Yordy B, Lakhani SA, Kuan C-Y et al (2014) Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell 159: 1563 – 1577
39. West AP, Khoury-Hanold W, Staron M, Tal MC, Pineda CM, Lang SM, Bestwick M, Duguay BA, Raimundo N, MacDuff DA et al (2015) Mitochondrial DNA stress primes the antiviral innate immune response. Nature 520: 553 – 557
40. Saffran HA, Pare JM, Corcoran JA, Weller SK, Smiley JR (2007) Herpes simplex virus eliminates host mitochondrial DNA. EMBO Rep 8: 188 – 193
41. Corcoran JA, Saffran HA, Duguay BA, Smiley JR (2009) Herpes simplex virus UL125 targets mitochondria through a mitochondrial localization sequence proximal to the N terminus. J Virol 83: 2601 – 2610
42. Duguay BA, Saffran HA, Ponomarev A, Duley SA, Eaton HE, Smiley JR, Sandri-Goldin RM (2014) Elimination of mitochondrial DNA is not required for herpes simplex virus 1 replication. J Virol 88: 2967 – 2976
43. Grady LM, Szczepaniak R, Murelli RP, Masaoka T, Le Grice SF, Wright DL, Weller SK (2017) The exonuclease activity of herpes simplex virus 1 UL12 is required for production of viral DNA that can be packaged to produce infectious virus. J Virol 91: 194 – 17
44. Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Etison JL, Mar KB, Richardson RB, Ratushny AV, Litvak V et al (2014) Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505: 691 – 695
45. Sun B, Sundstrom KB, Chew JJ, Bist P, Gan ES, Tan HC, Goh KC, Chawla T, Tang CK, Ooi EE (2017) Dengue virus activates cGAS through the release of mitochondrial DNA. Sci Rep 7: 1148 – 1148
46. Aguirre S, Luthra P, Sanchez-Aparicio MT, Maestre AM, Patel J, Lamothe F, Fredericks AC, Tripathi S, Zhu T, Pintado-Silva J et al (2017) Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. Nat Microbiol 2: 17037 – 11
47. Lai JH, Wang MY, Huang CY, Wu CH, Hung LF, Yang C-Y, Ke P-Y, Luo SF, Liu SJ, Ho LJ (2018) Infection with the dengue RNA virus activates TLR9 signaling in human dendritic cells. EMBO Rep 19: e46182 – 17
48. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D, Maringer K, Bernal-Rubio D, Shabman RS, Simon V et al (2012) DENV inhibits type I IFN production in infected cells by cleaving human STING. PloS Pathog 8: e1002934 – 14
49. Yu C-Y, Chang T-H, Liang J-J, Chiang R-L, Lee Y-L, Liao C-L, Lin Y-L (2012) Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PloS Pathog 8: e1002780 – 13
50. Wassermann R, Gulen MF, Sala C, Perin SG, Lou Y, Rybniker J, Schmid-Burgk JL, Schmidt T, Hornung V, Cole ST et al (2015) Mycobacterium tuberculosis differentially activates cGAS- and inflammasome-depen
dential intracellular immune responses through ESX-1. Cell Host Microbe 17: 799 – 810
51. Collins AC, Cai H, Li T, Franco LH, Li X-D, Mair CR, Levine B, Chen ZJ et al (2015) Cyclic GMP-AMP synthase is an innate immune DNA sensor for Mycobacterium tuberculosis. Cell Host Microbe 17: 820 – 828
52. Watson RO, Bell SL, MacDuff DA, Kimmey JM, Diner EJ, Olivas J, Vance RE, Stallings CL, Virgin HW, Cox JS (2015) The cytotoxic sensor cGAS detects Mycobacterium tuberculosis DNA to induce type I interferons and activate autophagy. Cell Host Microbe 17: 811 – 819
53. Wiens KE, Ernst JD (2016) The mechanism for type I interferon induction by Mycobacterium tuberculosis is bacterial strain-dependent. PloS Pathog 12: e1005809 – e1005820
54. Abarca-Rojo E, Rosas-Medina P, Zamudio-Cortez P, Mondragón-Flores R, Sánchez-García FJ (2003) Mycobacterium tuberculosis virulence correlates with mitochondrial cytochrome c release in infected macrophages. Scand J Immunol 58: 419 – 427
55. Aarekreberg LD, Esser-Nobis K, Driscoll C, Shuvarikov A, Roby JA, Gale M (2019) Interleukin-1β induces mtDNA release to activate innate immune signaling via cGAS-STING. Mol Cell 74: 801 – 815.e806
56. Orzalli MH, Smith A, Jurado KA, Iwasaki A, Garlick JA, Kagan JC (2018) An antiviral branch of the IL-1 signaling pathway restricts immune-evasive virus replication. Mol Cell 71: 825 – 840.e826
57. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W et al (2014) Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crossstalk. Nature 511: 99 – 103
58. Copenhaver AM, Casson CN, Nguyen HT, Duda MM, Shin S (2015) IL-1R signaling enables bystander cells to overcome bacterial blockade of host protein synthesis. Proc Natl Acad Sci USA 112: 7557 – 7562
59. Bock FJ, Taft SWG (2019) Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol 17: 608
60. Ning X, Wang Y, Jing M, Sha M, Lv M, Gao P, Zhang R, Huang X, Fung J-M, Jiang Z (2019) Apoptotic caspases suppress type I interferon production via the cleavage of cGAS, MAVS, and IRF3. Mol Cell 74: 19 – 31.e7
61. Riley JS, Quarto G, Cloix C, Lopez J, O Prey J, Pearson M, Chapman J, Sasaki H, Carlin LM, Passos JF et al (2018) Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis. EMBO J 37: e99238
62. McArthur K, Whitehead LW, Heddleston JM, Li L, Padman BS, Oorschot V, Geoghegan ND, Chappaz S, Davidson S, San Chin H et al (2018) BAK/ BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science 359: eaao6047
63. Ader NR, Hoffmann PC, Caneva I, Borgeaud AC, Wang C, Youle RJ, Kukulski W (2019) Molecular and topological reorganizations in mito
chondrial architecture interplay during Bax-mediated steps of apopto
sis. Elife 8: 303
64. Giampazolias E, Zunino B, Dhayade S, Bock F, Cloix C, Cao K, Roca A, Lopez J, Ichim G, Proics E et al (2017) Mitochondrial permeabilization
engages NF-κB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol 19: 1116–1129.

65. Abe T, Barber GN (2014) Cytoplasmic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-κB activation through TANK1. J Virol 88: 5328–5341.

66. von Ahlsen O, Renken C, Perkins G, Kluck RM, Bossy-Wetzel E, Newmeyer DD (2000) Preservation of mitochondrial structure and function after Bid- or Bax-mediated cytochrome c release. J Cell Biol 150: 1027–1036.

67. Waterhouse NJ, Goldstein JC, von Ahlsen O, Schuler M, Newmeyer DD, Green DR (2001) Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J Cell Biol 153: 319–328.

68. Bossy-Wetzel E, Newmeyer DD, Green DR (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 17: 37–49.

69. Huber HJ, Dussmann H, Kilbride SM, Rehm M, Prehn JHM (2011) Glucose metabolism determines resistance of cancer cells to bioenergetic crisis after cytochrome-c release. Mol Syst Biol 7: 470–470.

70. Potts MB, Vaughn AE, McDonough H, Patterson C, Deshmukh M (2005) Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP. J Cell Biol 171: 925–930.

71. Chen Q, Boire A, Jin X, Valiente M, Er EE, López-Soto A, Jacob LS, Patwa R, Shah H, Xu K et al (2016) Carcinoma–astrocyste gap junctions promote brain metastasis by cGAMP transfer. Nature 533: 493–498.

72. Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH (2018) Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity 49: 754–763.e754.

73. Karikó K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165–175.

74. Dhir A, Dhir S, Borowski LS, Jimenez L, Teittil M, Rötg A, Crow YJ, Rice GI, Duffy D, Tamby C et al (2018) Mitochondrial double-stranded RNA triggers antiviral signalling in humans. Nature 560: 238–242.

75. Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giannopaulas E, Delgado ME, Haller M, Riley JS, Mason SM, Athineos D et al (2015) Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell 57: 860–872.

76. Brokatzsky D, Dörfinger B, Haimovici A, Weber A, Kirschnek S, Vier J, Metz A, Henschel J, Steinfeldt T, Gentle IE et al (2019) A non-death function of the mitochondrial apoptosis apparatus in immunity. EMBO J 38: e100907.

77. Patrushev M, Kasymov V, Patrusheva V, Ushakovia T, Gogadze V, Gaziev AI (2006) Release of mitochondrial DNA fragments from brain mitochondria of irradiated mice. Mitochondrion 6: 43–47.

78. Patrushev M, Kasymov V, Patrusheva V, Ushakovia T, Gogadze V, Gaziev A (2004) Mitochondrial permeability transition triggers the release of mtDNA fragments. Cell Mol Life Sci 61: 3100–3103.

79. Izzo V, Bravo-San Pedro JM, Sica V, Kroemer G, Galluzzi L (2016) Mitochondrial permeability transition: new findings and persisting uncertainties. Trends Cell Biol 26: 655–667.

80. Bernardi P (1999) Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiol Rev 79: 1127–1155.

81. Halestrap AP, Mccay GP, Clarke SJ (2002) The permeability transition pore complex: another view. Biochimie 84: 153–166.

82. García N, García JJ, Correa F, Chávez E (2005) The permeability transition pore as a pathway for the release of mitochondrial DNA. Life Sci 76: 2873–2880.

83. García N, Chávez E (2007) Mitochondrial DNA fragments released through the permeability transition pore correspond to specific gene size. Life Sci 81: 1160–1166.

84. Carroll EC, Jin L, Mori A, Muñoz-Wolf N, Oleszycza E, Moran HBT, Mansouri S, McEntee CP, Lambe E, Agger EM et al (2016) The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity 44: 597–608.

85. Kim J, Gupta R, Blanco LP, Yang S, Shteinfler-Kuzmíne A, Wang K, Zhu J, Yoon HE, Wang X, Kerkhofs M et al (2019) VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science 366: 1331–1356.

86. Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, Malech HL, Ledbetter JA, Elkon KB, Kaplan MJ (2016) Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med 22: 146–153.

87. Caielli S, Athale S, Domic B, Murat E, Chandra M, Banchereau R, Baisch J, Phelps K, Clayton S, Gong M et al (2016) Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J Exp Med 213: 697–713.

88. Crow YJ, Manel N (2015) Aicardi-Goutières syndrome and the type I interferonopathies. Nat Rev Immunol 15: 429–440.

89. Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, Black DN, van Bokhoven H, Brunner HG, Hamel BC et al (2006) Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS locus. Nature Genet 38: 917–920.

90. Namjou B, Kothari PH, Kelly JA, Glenn SB, Ojwang JD, Adler A, Alarcón-Riquelme ME, Gallant Cj, Boackle SA, Criswell LA et al (2011) Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun 12: 270–279.

91. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee Y-A, de Silva U, Bailey SL, Witte T, Vyse TJ et al (2007) Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 39: 1065–1067.

92. Stetson DB, Ko JS, Heidmann T, Medzhivot R (2008) Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134: 587–598.

93. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J (2010) The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 11: 1005–1013.

94. Gall A, Treuting P, Elkon KB, Loo Y-M, Gale M Jr, Barber GN, Stetson DB (2012) Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36: 120–131.

95. Ablasser A, Hemmerling T, Schmid-Burgk JL, Behrendt R, Roers A, Hornung V (2014) TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J Immunol 192: 5993–5997.

96. Ahn J, Ruiz P, Barber GN (2014) Intrinsic Self-DNA triggers inflammatory disease dependent on STING. J Immunol 193: 4634–4642.

97. Gray EE, Treuting PM, Woodward J, Stetson DB (2015) Cutting edge cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi-Goutières syndrome. J Immunol 195: 1939–1943.
98. Gao D, Li T, Li X-D, Chen X, Li Q-Z, Wight-Carter M, Chen ZJ (2015) Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc Natl Acad Sci USA 112: E5699–E5705

99. Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, Griffith E, Ali M, Semple C, Aicardi J, Babul-Hirji R et al (2006) Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat Genet 38: 910–916

100. Rice GI, Bond J, Aspíu A, Brunette RL, Manfield IW, Fuller JC, Jackson RM, Lamb T, Briggs TA et al (2009) Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Neurosci 41: 829–832

101. Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GMA, Gornall HL, Oojageer A, Anderson B, Pizzino A, Helman G et al (2015) Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A 167A: 296–312

102. Günther C, Kind B, Reijns MAM, Berndt N, Martinez-Bueno M, Wolf C, Tüngler V, Chara O, Lee Y-A, Hübner N et al (2015) Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest 125: 413–424

103. Liu Y, Jesús AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS et al (2014) Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371: 507–518

104. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg M-C, Goudin N, Frémond M-L, Nitschke P, Molina TJ et al (2014) Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest 124: 5516–5520

105. Rodero MP, Tesser A, Bartok E, Rice GI, Mina Della E, Depp M, Beitz B, Bondet V, Cagnard N, Duffy D et al (2017) Type I interferon-mediated autoinflammation due to Dnase1 II deficiency. Nat Commun 8: 2176–15

106. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioaka Y, Yoshikawa H, Nagata S (2006) Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 443: 998–1002

107. Ahn J, Gutman D, Saijo S, Barber GN (2012) STING manifests self-DNA-dependent inflammatory disease. Proc Natl Acad Sci USA 109: 19386–19391

108. Baum R, Sharma S, Carpenter S, Li Q-Z, Buste P, Fitzgerald KA, Marshak-Rothstein A, Gravallese EM (2015) Cutting edge: AIM2 and endosomal TLRs differentially regulate arthritis and autoantibody production in DNase II-deficient mice. J Immunol 194: 873–877

109. Jakobs C, Perner S, Hornung V (2015) AIM2 drives joint inflammation in a Self-DNA triggered model of chronic polyarthritis. PLoS ONE 10: e0131702

110. King KR, Aguirre AD, Ye Y-X, Sun Y, Roh JD, Ng RP, Kohler RH, Arlauckas SP, lwamoto Y, Savol A et al (2017) IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat Med 23: 1481–1487

111. Cao DJ, Schiattarella GG, Villalobos E, Jiang N, May HI, Li T, Chen ZJ, Gillette TG, Hill JA (2014) Cytosolic DNA sensing promotes macrophage transformation and governs myocardial ischemic injury. Circulation 137: 2613–2634

112. Wang L, Xie L, Zhang Q, Cai X, Tang Y, Wang L, Hang T, Liu J, Gong J (2015) Plasma nuclear and mitochondrial DNA levels in acute myocardial infarction patients. Coron Arter Dis 26: 296–300

113. Bilksen M, Maniero LH, Ohm IK, Haugen F, Yndestad A, Solheim S, Seljeflot I, Ranheim T, Andersen GØ, Aukrust P et al (2012) Increased circulating mitochondrial DNA after myocardial infarction. Int J Cardiol 158: 132–134

114. Liu X-M, Du L-L (2015) A selective autophagy pathway takes an unconventional route. Autophagy 11: 2381–2382

115. Vincent J, Adura C, Gao P, Luz A, Lama L, Asano Y, Okamoto R, Imaeda T, Aida J, Rothamel K et al (2017) Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice. Nat Commun 8: 750–13

116. Lama L, Adura C, Xie W, Tomita D, Kamei T, Kuryayyi V, Gogakos T, Steinberg JI, Miller M, Ramos-Espíritu L et al (2019) Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression. Nat Commun 10: 2261–14

117. Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, Heymann M, van der Goot FG, Turcatti G, Behrendt R et al (2018) Targeting STING with covalent small-molecule inhibitors. Nature 559: 269–273

118. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNγamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107–1111

119. Woo S-R, Fuertes MB, Corrales L, Spranger S, Furdujy MJ, Leung MYK, Duggan R, Wang Y, Barber GN, Fitzgerald KA et al (2014) STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41: 830–842

120. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li X-D, Mauceri H, Beckett M, Darga T et al (2014) STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41: 843–852

121. Klarsquist J, Hennies CM, Lehn MA, Reboulet RA, Feau S, Janssen EM (2014) STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J Immunol 193: 6124–6134

122. Xu MM, Pu Y, Han D, Shi Y, Cao X, Liang H, Chen X, Li X-D, Deng L, Chen ZJ et al (2017) Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein α signaling. Immunity 47: 363–373.e365

123. Ahn J, Xia T, Rabasa Capote A, Betancourt D, Barber GN (2018) Extrinsc phagocyte-dependent STING signaling dictates the immunogenicity of dying cells. Cancer Cell 33: 862–873.e865

124. Torralba D, Baixauli F, Villarroya-Beltrí C, Fernández-Delgado I, Latorre-Pellicer A, Acín-Pérez R, Martín-Cófreces NB, Jaso-Tamame ÁL, Iborra S, Jorge I et al (2018) Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts. Nat Commun 9: 2658

125. Kitai Y, Kawasaki T, Sueyoshi T, Kobiyama K, Ishii KJ, Zou J, Akira S, Matsuda T, Kawai T (2017) DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent path- way and reinforce antitumor immunity. J Immunol 198: 1649–1659

126. Berger G, Marloye M, Lawler SE (2019) Pharmacological modulation of the STING pathway for cancer immunotherapy. Trends Mol Med 25: 412–427

127. Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang S-Y, Tran J-L, Moore P, Lehmann S, Eberl HC et al (2018) Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564: 439–443

128. Riley JS, Tait SWG (2016) Mechanisms of mitophagy: putting the powerhouse into the doghouse. Biol Chem 397: 617–635

129. Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, Bentivoglio AR (2004) PINK1 mutations are
associated with sporadic early-onset parkinsonism. *Ann Neurol* 56: 336–341.

130. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 392: 605–608.

131. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denéfle P, Wood NW et al (2000) Association between early-onset Parkinson’s disease and mutations in the parkin gene. *N Engl J Med* 342: 1560–1567.

132. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, Bouley S, Vaughan JR, Gasser T, Marconi R et al (1999) A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s Disease. *Hum Mol Genet* 8: 567–574.

133. West A, Periquet M, Lincoln S, Lucking CB, Nicholl D, Bonifati V, Rawal N, Gasser T, Lohmann E, Deleuze J-F et al (2002) Complex relationship between Parkin mutations and Parkinson disease. *Am J Med Genet* 114: 584–591.

134. Gladkova C, Maslen SL, Skelhel JM, Komander D (2018) Mechanism of parkin activation by PINK1. *Nature* 559: 410–414.

135. Lazarou M, Sliter DA, Kane LA, Sarraf SA, Wang C, Burman JL, Sideris DP, Fogel AI, Youle RJ (2018) Mechanism of mitochondrial DNA synthesis enables NLRP3 inflammasome activation. *Nature* 560: 198–203.

136. Shimada K, Crother TR, Karlin J, Dagradorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM et al (2012) Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity* 36: 401–414.

137. Zhou R, Yazdi AS, Menu P, Tschopp J (2011) A role for mitochondria in NLRP3 inflammasome activation. *Nature* 469: 221–225.

138. Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, He F, Boassa D, Perkins C, Ali SR et al (2016) NF-κB restricts inflammasome activation via elimination of damaged mitochondria. *Cell* 164: 896–910.

139. Broz P, Dixit VM (2016) Inflammasomes: mechanism of assembly, regulation and signalling. *Nat Rev Immunol* 16: 407–420.

140. Nakahira K, Haspel JA, Rathinam VAK, Lee S-J, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP et al (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nat Immunol* 12: 222–230.

141. Yousei S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlovska E, Schmid I, Straumann A, Reichenbach J, Gleich GJ et al (2008) Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. *Nat Med* 14: 949–953.

142. Ingelsson B, Söderberg D, Strid T, Söderberg A, Bergh A-C, Lotfi V, Lotf K, Segelmark M, Spyrou G, Rosen A (2018) Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C. *Proc Natl Acad Sci USA* 115: E478–E487.

143. Amiri P, Stojkov D, Felser A, Jackson CB, Courage C, Schaller A, Gelman L, Soriano ME, Nuoffer J-M, Scorrano L et al (2018) Neutrophil
extracellular trap formation requires OPA1-dependent glycolytic ATP production. Nat Commun 9: 2958 – 16
162. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM (2001) Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167: 3555 – 3558
163. Ahmad-Nejad P, Hääcker H, Rutz M, Bauer S, Vabulas RM, Wagner H (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32: 1958 – 1968
164. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ, Segal DM (2004) TLRR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 173: 1179 – 1183
165. Latz E, Schoenemeyer A, Visentin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5: 190 – 198
166. Cardon LR, Burge C, Clayton DA, Karlin S (1994) Pervasive CpG suppression in animal mitochondrial genomes. Proc Natl Acad Sci USA 91: 3803–3807
167. Pollack Y, Kasir J, Shemer R, Metzger S, Szyf M (1984) Methylation pattern of mouse mitochondrial DNA. Nucleic Acids Res 12: 4821 – 4824
168. Zhang Q, Raafoe M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104 – 107
169. Zhang Q, Itagaki K, Hauser CJ (2010) Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock 34: 55 – 59
170. Nakai A, Yamaguchi O, Takeda K, Higuchi Y, Hikosato S, Tanike M, Omiya S, Mizote I, Matsumura Y, Asahi M et al (2007) The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 13: 619 – 624
171. Oka T, Hikosato S, Yamaguchi O, Taneike M, Takeda T, Tamai T, Oyabu J, Murakawa T, Nakayama H, Nishida K et al (2012) Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485: 251 – 255
172. Zhang Z, Meng P, Han Y, Shen C, Li B, Hakim MA, Zhang X, Lu Q, Rong M, Lai R (2015) Mitochondrial DNA-LL-37 complex promotes atherosclerosis by escaping from autophagic recognition. Immunity 43: 1137 – 1147
173. Scafﬁdi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inﬂammation. Nature 418: 191 – 195
174. Wang H, Bloom O, Zhang M, Vishnubhatla JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L et al (1999) HMGC-1 as a late mediator of endotoxin lethality in mice. Science 285: 248 – 251
175. Tian J, Avalos AM, Mao S-Y, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sroiss E et al (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8: 487 – 493
176. Julian MW, Shao G, Bao S, Knodell DL, Papenfuss TL, VanGundy ZC, Crouser ED (2012) Mitochondrial transcription factor A serves as a danger signal by augmenting plasmacytoid dendritic cell responses to DNA. J Immunol 189: 433 – 443
177. Julian MW, Shao G, VanGundy ZC, Papenfuss TL, Crouser ED (2013) Mitochondrial transcription factor A, an endogenous danger signal, promotes TNFα release via RAGE- and TLR9-responsive plasmacytoid dendritic cells. PLoS ONE 8: e72354
178. Liu X, He Y, Li F, Huang Q, Kato TA, Hall RP, Li C-Y (2015) Caspase-3 promotes genetic instability and carcinogenesis. Mol Cell 58: 284 – 296
179. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell RA, Mehal WZ (2009) Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 119: 305 – 314
180. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, Mehal WZ (2007) Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 46: 1509 – 1518
181. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky J, Brenner DA, Saki E (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139: 323 – 34.e327
182. Koliaki C, Szentroedi J, Kaul K, Jelenik T, Novotny P, Jankowiak F, Herder C, Carstensen M, Krausch M, Knoel ef WT et al (2015) Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 21: 739 – 746
183. Garcia-Martinez I, Santoro N, Chen Y, Hoque R, Ouyang X, Caprio S, Shlomchik MJ, Coffman RL, Candia A, Mehal WZ (2016) Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLRR9. J Clin Invest 126: 859 – 864
184. Feldstein AE, Canbay A, Angulo P, Tanai M, Burgart LJ, Lindor KD, Gores GJ (2008) Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125: 437 – 443
185. Afonso MB, Rodrigues PM, Carvalho T, Caridade M, Borrallio P, Cortez-Pinto H, Castro RE, Rodrigues CMP (2010) Mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. J Immunol 184: 1917 – 1922
186. Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C, Kreggenwinkel K, Schneider AT, Bantecne M, Neumann UP et al (2014) A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 6: 1062 – 1074
187. Saito Y, Hikita H, Nozaki Y, Kito Y, Makino Y, Nakabori T, Tanaka S, Yamada R, Shigekawa M, Kodama T et al (2019) DNase II activated by the mitochondrial apoptotic pathway regulates RIP-dependent non-apoptotic hepatocyte death via the TLR9/IFN-β signaling pathway. Cell Death Differ 26: 470 – 486
188. Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissière A, Campos Y, Rivera H, la de Aleja JC, Carroccia R et al (2008) OPA1 mutations induce mitochondrial DNA instability and optic atrophy “plus” phenotypes. Brain 131: 338 – 351
189. Hudson G, Amati-Bonneau P, Blakely EL, Stewart JD, He L, Schaefer AM, Griffiths PG, Ahlgvist K, Suomalainen A, Reynier P et al (2008) Mutation of OPA1 causes dominant optic atrophy with external ophthalmitisplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maturation. Brain 131: 329 – 337
190. Kim JY, Hwang J-M, Ko HS, Seong M-W, Park BJ, Park SS (2005) Mitochondrial DNA content is decreased in autosomal dominant optic atrophy “plus” phenotypes. Brain 131: 338 – 351
191. Yu-Wai-Man P, Sitarz KS, Samuels DC, Griffiths PG, Reeve AK, Bindoff LA, Horvath R, Chinnery PF (2010) OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. Hum Mol Genet 19: 3043 – 3052
192. Tesce C, Romanello V, Desbats MA, Fadini GP, Albiero M, Favaro G, Ciciliot S, Soriano ME, Morbidion V, Cerqua C et al (2017) Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic
homeostasis, systemic inflammation, and epithelial senescence. Cell Metab 25: 1374 – 1389.e1376
193. Pereira RO, Tadinada SM, Zasadny FM, Oliveira KJ, Pires KMP, Olvera A, Jeffers J, Souvenir R, Mcglaflin R, Seei A et al (2017) OPAL deficiency promotes secretion of FGF21 from muscle that prevents obesity and insulin resistance. EMBO J 36: 2126 – 2145
194. Rodríguez Nuevo A, Díaz Ramos A, Noguera E, Díaz Sáez F, Duran X, Muñoz JP, Romero M, Planà N, Sebastián D, Tezze C et al (2018) Mitochondrial DNA and TLR9 drive muscle inflammation upon Opa1 deficiency. EMBO J 37:e96553 – 18
195. King MP, Attardi G (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246: 500 – 503
196. Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, Ji X, Lo EH (2016) Transfer of mitochondria from astrocytes to neurons after stroke. Nature 535: 551 – 555
197. Tan AS, Baty JW, Dong L-F, Bezawork-Geleta A, Endaya B, Goodwin J, Bajzikova M, Kovalova J, Yan B et al (2015) Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab 21: 81 – 94
198. Rustom A, Saffrich R, Markovic I, Walther P, Gerdes H-H (2004) Nanotubular highways for intercellular organelle transport. Science 303: 1007 – 1010
199. Pasquier J, Guerrouahen BS, Thwadi Al H, Chabi P, Maleki M, Abou-Kaoud N, Jacob A, Mirshahi M, Galas L, Rafii S et al (2013) Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. J Transl Med 11: 94
200. Wang X, Gerdes H-H (2015) Transfer of mitochondria via tunneling nanotubes rescues apoptotic PC12 cells. Cell Death Differ 22: 1181 – 1191

201. Sansone P, Savini C, Kurelac I, Chang Q, Amato LB, Strillacci A, Sten奖学ona A, Iommarini L, Mastroloeo C, Daly L et al (2017) Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad Sci USA 114: E9066 – E9075
202. Dong L-F, Kovalova J, Bajzikova M, Bezawork-Geleta A, Svec D, Endaya B, Sachaphibulkj K, Coelho AR, Sekova N, Ruzicková A et al (2017) Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells. Elife 6: 529
203. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, Rowlands DJ, Quadri SK, Bhattacharya S, Bhattacharya J (2012) Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 18: 759 – 765
204. Ishikawa K, Toyama-Sorimachi N, Nakada K, Morimoto M, Imanishi H, Yoshizaki M, Sasawatari S, Niikura M, Takenaga K, Yonekawa H et al (2010) The innate immune system in host mice targets cells with allogenic mitochondrial DNA. J Exp Med 207: 2297 – 2305
205. Schäfer ST, Franken L, Adamzik M, Schumak B, Scherag A, Schönborn N, Walden J, Koch S, Baba HA et al (2016) Mitochondrial DNA: an endogenous trigger for immune paralysis. Anesthesiology 124: 923 – 933
206. Wiley CD, Velarde MC, Lecot P, Liu S, Sarnoski EA, Freund A, Shirakawa K, Lim HW, Davis SS, Ramanathan A et al (2016) Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. Cell Metab 23: 303 – 314

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.